Sophie-Beth is a Chartered (UK) Patent Attorney and European Patent Attorney in the biotechnology and life sciences fields with particular specialist knowledge in immunotherapy, antibodies, cancer therapeutics, vaccines and diagnostics. She has extensive experience advising a range of clients including first-time inventors, start-ups and SME's to large established corporations and overseas associates.
Sophie-Beth acts before the UKIPO, EPO and WIPO. Her work includes drafting, filing and prosecuting patent applications, post-grant opposition and appeal proceedings before the EPO and matters relating to IP due diligence. Sophie-Beth focuses on providing commercially relevant, pragmatic advice to clients in line with their business objectives and is proactive in coordinating the strategic planning and management of clients' patent portfolios.
Sophie-Beth is a member of the HGF Venture team with Kerry Rees and provides IP due diligence service to life science investors. Consequently, Sophie-Beth also works with early stage companies to help them align their IP strategies with their business plan to maximise the return on investment.
Sophie-Beth graduated with a first class degree in Pharmacology from the University of Bath. As part of her degree, she spent a year working at a leading biopharmaceutical company, UCB. Sophie-Beth then went on to gain a PhD in Metabolic Biochemistry from University College London. Her research focused on the genetic and biochemical mechanisms responsible for the central folate deficiency associated with mitochondrial disorders.
MPharmacol (Hons) in Pharmacology
PhD in Metabolic Biochemistry
Postgraduate Certificate in Intellectual Property Law
Certificate in Basic Litigation Skills
Medical Technology Ireland Conference 2022 will be held on 21-22 September at the Galway Racecource. Medical Technology Ireland is a new high-profile National and International event attracting global suppliers to …Event details
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.